Alembic Pharmaceuticals’ JV gets final approval for Tavaborole Topical Solution

22 Oct 2020 Evaluate

Alembic Pharmaceuticals’ joint venture Aleor Dermaceuticals (Aleor) has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Tavaborole Topical Solution, 5%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Topical Solution, 5%, of Anacor Pharmaceuticals, Inc. (Anacor).

Aleor had previously received tentative approval for this ANDA. Tavaborole Topical Solution, 5% has an estimated market size of $82 million for twelve months ending June 2020. Alembic has a cumulative total of 133 ANDA approvals (116 final approvals and 17 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharma Share Price

841.00 -7.20 (-0.85%)
01-Jan-2026 11:15 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1713.25
Dr. Reddys Lab 1251.20
Cipla 1503.90
Zydus Lifesciences 911.65
Lupin 2089.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×